nach oben

Erschienen in:

23.11.2017 | Laboratory Investigation

An immune-related lncRNA signature for patients with anaplastic gliomas

verfasst von: Wen Wang, Zheng Zhao, Fan Yang, Haoyuan Wang, Fan Wu, Tingyu Liang, Xiaoyan Yan, Jiye Li, Qing Lan, Jiangfei Wang, Jizong Zhao

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

We investigated immune-related long non-coding RNAs (lncRNAs) that may be exploited as potential therapeutic targets in anaplastic gliomas. We obtained 572 lncRNAs and 317 immune genes from the Chinese Glioma Genome Atlas microarray and constructed immune-related lncRNAs co-expression networks to identify immune-related lncRNAs. Two additional datasets (GSE16011, REMBRANDT) were used for validation. Gene set enrichment analysis and principal component analysis were used for functional annotation. Immune-lncRNAs co-expression networks were constructed. Nine immune-related lncRNAs (SNHG8, PGM5-AS1, ST20-AS1, LINC00937, AGAP2-AS1, MIR155HG, TUG1, MAPKAPK5-AS1, and HCG18) signature was identified in patients with anaplastic gliomas. Patients in the low-risk group showed longer overall survival (OS) and progression-free survival than those in the high-risk group (P < 0.0001; P < 0.0001). Additionally, patients in the high-risk group displayed no-deletion of chromosomal arms 1p and/or 19q, isocitrate dehydrogenase wild-type, classical and mesenchymal TCGA subtype, G3 CGGA subtype, and lower Karnofsky performance score (KPS). Moreover, the signature was an independent factor and was significantly associated with the OS (P = 0.000, hazard ratio (HR) = 1.434). These findings were further validated in two additional datasets (GSE16011, REMBRANDT). Low-risk and high-risk groups displayed different immune status based on principal components analysis. Our results showed that the nine immune-related lncRNAs signature has prognostic value for anaplastic gliomas.

Nur mit Berechtigung zugänglich

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4 CrossRefPubMedPubMedCentral

Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, Bao Z, Wang Y, Qiu X, Jiang T (2013) Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. J. Neuro-oncol 113(2):259–266. https://doi.org/10.1007/s11060-013-1103-9 CrossRef

Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, Wu A (2016) Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology 86(24):2226–2234. https://doi.org/10.1212/WNL.0000000000002770 CrossRefPubMed

Silver DJ, Sinyuk M, Vogelbaum MA, Ahluwalia MS, Lathia JD (2016) The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol 18(2):153–159. https://doi.org/10.1093/neuonc/nov157 CrossRefPubMed

Finocchiaro G, Pellegatta S (2011) Immunotherapy for glioma: getting closer to the clinical arena? Curr Opin Neurol 24(6):641–647. https://doi.org/10.1097/WCO.0b013e32834cbb17 CrossRefPubMed

Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155–159. https://doi.org/10.1038/nrg2521 CrossRefPubMed

Fang Y, Fullwood MJ (2016) Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinf. https://doi.org/10.1016/j.gpb.2015.09.006

Bian EB, Li J, Xie YS, Zong G, Li J, Zhao B (2015) LncRNAs: new players in gliomas, with special emphasis on the interaction of lncRNAs With EZH2. J Cell Physiol 230(3):496–503. https://doi.org/10.1002/jcp.24549 CrossRefPubMed

Sun Y, Wang Z, Zhou D (2013) Long non-coding RNAs as potential biomarkers and therapeutic targets for gliomas. Med Hypotheses 81(2):319–321. https://doi.org/10.1016/j.mehy.2013.04.010 CrossRefPubMed

10.

Zhang XQ, Leung GK (2014) Long non-coding RNAs in glioma: functional roles and clinical perspectives. Neurochem Int 77:78–85. https://doi.org/10.1016/j.neuint.2014.05.008 CrossRefPubMed

11.

Wang P, Ren Z, Sun P (2012) Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem 113(6):1868–1874. https://doi.org/10.1002/jcb.24055 CrossRefPubMed

12.

Carpenter S, Aiello D, Atianand MK, Ricci EP, Gandhi P, Hall LL, Byron M, Monks B, Henry-Bezy M, Lawrence JB, O’Neill LA, Moore MJ, Caffrey DR, Fitzgerald KA (2013) A long noncoding RNA mediates both activation and repression of immune response genes. Science 341(6147):789–792. https://doi.org/10.1126/science.1240925 CrossRefPubMedPubMedCentral

13.

Atianand MK, Hu W, Satpathy AT, Shen Y, Ricci EP, Alvarez-Dominguez JR, Bhatta A, Schattgen SA, McGowan JD, Blin J, Braun JE, Gandhi P, Moore MJ, Chang HY, Lodish HF, Caffrey DR, Fitzgerald KA (2016) A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell 165(7):1672–1685. https://doi.org/10.1016/j.cell.2016.05.075 CrossRefPubMedPubMedCentral

14.

Jiang R, Tang J, Chen Y, Deng L, Ji J, Xie Y, Wang K, Jia W, Chu WM, Sun B (2017) The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun 8:15129. https://doi.org/10.1038/ncomms15129 CrossRefPubMedPubMedCentral

15.

Wang Q, Zhang J, Liu Y, Zhang W, Zhou J, Duan R, Pu P, Kang C, Han L (2016) A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett 373(2):251–259. https://doi.org/10.1016/j.canlet.2016.01.039 CrossRefPubMed

16.

Han Y, Wu Z, Wu T, Huang Y, Cheng Z, Li X, Sun T, Xie X, Zhou Y, Du Z (2016) Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis 7:e2123. https://doi.org/10.1038/cddis.2015.407 CrossRefPubMedPubMedCentral

17.

Zhang CB, Zhu P, Yang P, Cai JQ, Wang ZL, Li QB, Bao ZS, Zhang W, Jiang T (2015) Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget 6(34):36643–36651. https://doi.org/10.18632/oncotarget.5421 PubMedPubMedCentral

18.

Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A (2015) A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget 6(30):29285–29295. https://doi.org/10.18632/oncotarget.4978 PubMedPubMedCentral

19.

Zhang X, Sun S, Pu JK, Tsang AC, Lee D, Man VO, Lui WM, Wong ST, Leung GK (2012) Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis 48(1):1–8. https://doi.org/10.1016/j.nbd.2012.06.004 CrossRefPubMed

20.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. https://doi.org/10.1073/pnas.0506580102 CrossRefPubMedPubMedCentral

21.

Cai J, Zhang W, Yang P, Wang Y, Li M, Zhang C, Wang Z, Hu H, Liu Y, Li Q, Wen J, Sun B, Wang X, Jiang T, Jiang C (2015) Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance. PLoS ONE 10(5):e0126022. https://doi.org/10.1371/journal.pone.0126022 CrossRefPubMedPubMedCentral

22.

Bao ZS, Li MY, Wang JY, Zhang CB, Wang HJ, Yan W, Liu YW, Zhang W, Chen L, Jiang T (2014) Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling. CNS Neurosci Ther 20(2):112–118. https://doi.org/10.1111/cns.12171 CrossRefPubMed

23.

Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350(18):1828–1837. https://doi.org/10.1056/NEJMoa032520 CrossRefPubMed

24.

Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T (2013) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119(4):814–824. https://doi.org/10.1002/cncr.27826 CrossRefPubMed

25.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504. https://doi.org/10.1101/gr.1239303 CrossRefPubMedPubMedCentral

26.

Wang ZL, Zhang CB, Cai JQ, Li QB, Wang Z, Jiang T (2015) Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas. J Exp Clin Cancer Res 34:127. https://doi.org/10.1186/s13046-015-0249-z CrossRefPubMedPubMedCentral

27.

Wang W, Zhang L, Wang Z, Yang F, Wang H, Liang T, Wu F, Lan Q, Wang J, Zhao J (2016) A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget. https://doi.org/10.18632/oncotarget.11726

28.

Wu Y, Liu H, Shi X, Yao Y, Yang W, Song Y (2015) The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget 6(11):9160–9172. https://doi.org/10.18632/oncotarget.3247 CrossRefPubMedPubMedCentral

29.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMed

30.

Wirsching HG, Weller M (2016) The role of molecular diagnostics in the management of patients with gliomas. Curr Treat Options Oncol 17(10):51. https://doi.org/10.1007/s11864-016-0430-4 CrossRefPubMed

31.

Bai H, Harmanci AS, Erson-Omay EZ, Li J, Coskun S, Simon M, Krischek B, Ozduman K, Omay SB, Sorensen EA, Turcan S, Bakirciglu M, Carrion-Grant G, Murray PB, Clark VE, Ercan-Sencicek AG, Knight J, Sencar L, Altinok S, Kaulen LD, Gulez B, Timmer M, Schramm J, Mishra-Gorur K, Henegariu O, Moliterno J, Louvi A, Chan TA, Tannheimer SL, Pamir MN, Vortmeyer AO, Bilguvar K, Yasuno K, Gunel M (2016) Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet 48(1):59–66. https://doi.org/10.1038/ng.3457 CrossRefPubMed

32.

Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, Forman SJ, Jensen MC (2014) Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother 37(2):93–104. https://doi.org/10.1097/CJI.0000000000000018 CrossRefPubMed

33.

Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE 2nd, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20 (4):972–984. https://doi.org/10.1158/1078-0432.CCR-13-0709 CrossRefPubMed

34.

Fine HA (2015) New strategies in glioblastoma: exploiting the new biology. Clin Cancer Res 21(9):1984–1988. https://doi.org/10.1158/1078-0432.CCR-14-1328 CrossRefPubMed

35.

Cheng W, Li M, Jiang Y, Zhang C, Cai J, Wang K, Wu A (2016) Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. J Neurosurg 125(1):7–16. https://doi.org/10.3171/2015.5.JNS142437 CrossRefPubMed

36.

Haasch D, Chen YW, Reilly RM, Chiou XG, Koterski S, Smith ML, Kroeger P, McWeeny K, Halbert DN, Mollison KW, Djuric SW, Trevillyan JM (2002) T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol 217(1–2):78–86CrossRefPubMed

37.

van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J, Blokzijl T, Jacobs S, Kluiver J, Diepstra A, Maggio E, Poppema S (2003) High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosom Cancer 37(1):20–28. https://doi.org/10.1002/gcc.10186 CrossRefPubMed

38.

Zhang T, Nie K, Tam W (2008) BIC is processed efficiently to microRNA-155 in Burkitt lymphoma cells. Leukemia 22(9):1795–1797. https://doi.org/10.1038/leu.2008.62 CrossRefPubMed

39.

Wu X, Wang Y, Yu T, Nie E, Hu Q, Wu W, Zhi T, Jiang K, Wang X, Lu X, Li H, Liu N, Zhang J, You Y (2017) Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. https://doi.org/10.1093/neuonc/nox017

40.

41.

Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 106(28):11667–11672. https://doi.org/10.1073/pnas.0904715106 CrossRefPubMedPubMedCentral

42.

Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N, Sato S, Takahashi S, Kimura H, Totoki Y, Shibata T, Naito M, Kim HJ, Miyata K, Kataoka K, Kondo Y (2016) Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun 7:13616. https://doi.org/10.1038/ncomms13616 CrossRefPubMedPubMedCentral

43.

Wang W, Gao F, Zhao Z, Wang H, Zhang L, Zhang D, Zhang Y, Lan Q, Wang J, Zhao J (2017) Integrated analysis of lncRNA-mRNA co-expression profiles in patients with moyamoya disease. Sci Rep 7:42421. https://doi.org/10.1038/srep42421 CrossRefPubMedPubMedCentral

44.

Xu J, Zhang F, Gao C, Ma X, Peng X, Kong D, Hao J (2016) Microarray analysis of lncRNA and mRNA expression profiles in patients with neuromyelitis optica. Mol Neurobiol. https://doi.org/10.1007/s12035-016-9754-0

45.

Li H, Wang W, Zhang L, Lan Q, Wang J, Cao Y, Zhao J (2017) Identification of a long noncoding RNA-associated competing endogenous RNA network in intracranial aneurysm. World Neurosurg 97:684–692. https://doi.org/10.1016/j.wneu.2016.10.016 CrossRefPubMed

46.

Reon BJ, Anaya J, Zhang Y, Mandell J, Purow B, Abounader R, Dutta A (2016) Expression of lncRNAs in low-grade gliomas and glioblastoma multiforme: an in silico analysis. PLoS Med 13(12):e1002192. https://doi.org/10.1371/journal.pmed.1002192 CrossRefPubMedPubMedCentral

Titel: An immune-related lncRNA signature for patients with anaplastic gliomas
verfasst von: Wen Wang
Zheng Zhao
Fan Yang
Haoyuan Wang
Fan Wu
Tingyu Liang
Xiaoyan Yan
Jiye Li
Qing Lan
Jiangfei Wang
Jizong Zhao
Publikationsdatum: 23.11.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2667-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT

Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma

Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma

Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy

Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors

Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma